

1st Announcement:

“Statistical Challenges in the Clinical Development of CAR-T Cell Therapies”

Monday, March 22, 2021


15:00 to 18:00 (CET)

Free BBS Webinar

Developing CAR-T Cell therapies has unique challenges not observed with traditional drugs. On top of the manufactory and logistical challenges, clinical development is facing unique statistical questions which need to be resolved for delivering view of the treatment effect.

The Basel Biometric Section (BBS) is pleased to host a scientific meeting on this relevant and far-reaching topic. The purpose is to bring together experts from the pharmaceutical industry, academia and the European and US regulatory bodies to present the current state of the art and discuss the statistical and other challenges and opportunities of CAR-T cell therapies.

Caroline ARBER BATH CHUV, Switzerland	Introduction: a clinical perspective
Elina ASIKANIUS FIMEA, Finland	Perspectives from EMA
Zhenzhen XU FDA, USA	Perspectives from FDA
Khadija RANTELL MHRA, UK	Treatment effect or therapeutic strategy effect?
Alessandro PREVITALI BMS, Switzerland	Estimands in the context of cell therapy development
Nigel YATEMAN Novartis, Switzerland	Challenges for new CAR-T therapies
Oriana CIANI Uni. Bocconi, Italy	Post-Approval challenges, reimbursement and HTA
Katerina BAKUNINA EBMT, Netherlands	Registries
Marcelo PASQUINI CIBMTR, USA	
Andrea SMITH G-BA, Germany	HTA / payer perspective
All speakers + Daniel LI , BMS, USA Frank PETAVY , EMA, NL	Panel discussion



Venue

Free BBS Webinar

[Click here to Register](#)

For information regarding registration and/or the scientific content, please feel free to contact any one of the webinar organizers:

Roland Marion-Gallois, BMS
Roland.Marion-Gallois@bms.com

Simon Newsome, Novartis
Simon.Newsome@novartis.com

Fred Sorenson, Xcenda
Fred.Sorenson@xcenda.com